DexCom, Inc. DXCM | NASDAQ
Company Overview:
10 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
DXCM Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for DXCM
Based on past 10-year performance, here are DXCM growth metrics:
Share price CAGR of +15.4%
Dividend CAGR of +0%
Using DXCM CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| DXCM (DRIP) | DXCM - No DRIP | |
|---|---|---|
| Current Price | $70.26 | $70.26 |
| Start Shares | 142.33 | 142.33 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 142.33 | 142.33 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $254.94 | $70.26 |
| Total Dividends | $0 | $0 |
| Final Value | $36,285 | $10,000 |
NOTE: Above numbers are our estimate based on DXCM's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
DexCom, Inc. (DXCM) had its IPO on 2005-04-14, and is trader on NASDAQ stock exchange.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM website: https://www.dexcom.com
